Tag: natural_killer_cells
-
Immune Activation Key to CAR T Therapy Success in Glioblastoma, Penn Medicine Finds
Penn Medicine research reveals glioblastoma patients on dual-target CAR T cell therapy live longer with activated natural killer cells, while non-responders show more immunosuppressive cells, paving the way for therapy improvements.
HealthBusinessPolitics and GovernmentLaw EnforcementMedical ScienceReal EstateGeneral PoliticsEnvironmentSocial Issues GlioblastomaCAR T cell therapyPenn MedicineNatural Killer CellsImmunosuppressionCancer ResearchImmunotherapy